Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Asan Medical Center | OTHER |
| Cardiovascular Clinical Research | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the clinical outcomes of transcatheter aortic valve Replacement (TAVR) in the Asian Pacific population
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| transcatheter aortic valve Replacement | Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcatheter aortic valve Replacement | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Death from any cause | 1 month | |
| Death from any cause | 6 months | |
| Death from any cause | 1 year | |
| Death from any cause | 2 years | |
| Death from any cause | 3 years | |
| Death from any cause | 4 years | |
| Death from any cause | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Death from cardiac cause | 1 month | |
| Death from cardiac cause | 6 months | |
| Death from cardiac cause |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All patients who had undergone transcatheter aortic valve replacement on the basis of inclusion criteria were prospectively&retrospectively included in the registry
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elly Jeong-youn Bae, Research Nurse | Contact | cvcrc10@amc.seoul.kr |
| Name | Affiliation | Role |
|---|---|---|
| Seung-jung Park, MD, PhD | Asan Medical Center, Republic of Korea | Principal Investigator |
| Edgar L.W. Tay, MD | National University Heart Center (National University Health System), Singapore | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Queen Elizabeth Hospital | Hong Kong | China |
Not provided
| ID | Term |
|---|---|
| D001024 | Aortic Valve Stenosis |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D065467 | Transcatheter Aortic Valve Replacement |
| ID | Term |
|---|---|
| D019918 | Heart Valve Prosthesis Implantation |
| D006348 | Cardiac Surgical Procedures |
| D013504 | Cardiovascular Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| Death from cardiac cause | 2 years |
| Death from cardiac cause | 3 years |
| Death from cardiac cause | 4 years |
| Death from cardiac cause | 5 years |
| Stroke | 1 month |
| Stroke | 6 months |
| Stroke | 1 year |
| Stroke | 2 years |
| Stroke | 3 years |
| Stroke | 4 years |
| Stroke | 5 years |
| Myocardial infarction | 1 month |
| Myocardial infarction | 6 months |
| Myocardial infarction | 1 year |
| Myocardial infarction | 2 years |
| Myocardial infarction | 3 years |
| Myocardial infarction | 4 years |
| Myocardial infarction | 5 years |
| Repeat hospitalization | 1 month |
| Repeat hospitalization | 6 months |
| Repeat hospitalization | 1 year |
| Repeat hospitalization | 2 years |
| Repeat hospitalization | 3 years |
| Repeat hospitalization | 4 years |
| Repeat hospitalization | 5 years |
| Acute kidney injury | 1 month |
| Acute kidney injury | 6 months |
| Acute kidney injury | 1 year |
| Acute kidney injury | 2 years |
| Acute kidney injury | 3 years |
| Acute kidney injury | 4 years |
| Acute kidney injury | 5 years |
| Vascular complication | 1 month |
| Vascular complication | 6 months |
| Vascular complication | 1 year |
| Vascular complication | 2 years |
| Vascular complication | 3 years |
| Vascular complication | 4 years |
| Vascular complication | 5 years |
| Bleeding events | 1 month |
| Bleeding events | 6 months |
| Bleeding events | 1 year |
| Bleeding events | 2 years |
| Bleeding events | 3 years |
| Bleeding events | 4 years |
| Bleeding events | 5 years |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 1 month |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 6 months |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 1 year |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 2 years |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 3 years |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 4 years |
| Device success | Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity < 3 m/s, and no moderate or severe paravalvular regurgitation) | 5 years |
| Machael Kang-Yin Lee, MD | Queen Elizabeth Hospital, HongKong | Principal Investigator |
| Nanjing 1st Hospital | Nanjing | China |
|
| Shonan Kamakura General Hospital | Kamakura | Japan |
|
| Institut Jantung Negara | Kuala Lumpur | Malaysia |
|
| St. Luke's Medical Center | Bonifacio | Philippines |
|
| National Heart Centre of Singapore | Singapore | Singapore |
|
| National University Heart Centre | Singapore | Singapore |
|
| Asan Medical Center | Seoul | South Korea |
|
| National Taiwan University | Taipei | Taiwan |
|
| King Chulalongkorn Memorial Hospital | Bangkok | Thailand |
|
| D014694 |
| Ventricular Outflow Obstruction |
| D019919 | Prosthesis Implantation |
| D019616 | Thoracic Surgical Procedures |